Suppr超能文献

为共感染设计的具有复制能力的流感病毒和呼吸道合胞病毒荧光素酶报告株在联合筛选中鉴定抗病毒化合物。

Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.

作者信息

Yan Dan, Weisshaar Marco, Lamb Kristen, Chung Hokyung K, Lin Michael Z, Plemper Richard K

机构信息

Institute for Biomedical Sciences, Georgia State University , Atlanta, Georgia 30303-3222, United States.

Department of Biology, Stanford University , Stanford, California 94305-5020, United States.

出版信息

Biochemistry. 2015 Sep 15;54(36):5589-604. doi: 10.1021/acs.biochem.5b00623. Epub 2015 Sep 1.

Abstract

Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.

摘要

甲型流感病毒(IAV)和呼吸道合胞病毒(RSV)等黏液病毒是主要的人类病原体,因此需要开发新型治疗方法。为建立一种高通量筛选方案,以同时鉴定针对病原体或两者的病原体靶向和宿主靶向的命中候选物,我们尝试用IAV和RSV共同感染细胞。然而,病毒复制动力学不兼容,RSV信号窗口较低,并且初始筛选中使用的IAV驱动的微型复制子报告基因检测缩小了宿主细胞范围,并将检测限制在单周期感染。为克服这些限制,我们开发了一种携带与创新的通用小分子辅助关闭结构域融合的萤火虫荧光素酶的RSV毒株,该毒株提高了检测信号窗口,以及一种超活性融合蛋白,该蛋白使IAV和RSV报告基因表达动力学同步,并抑制了对最近报道的RSV泛耐药机制敏感的RSV进入抑制剂的鉴定。结合携带纳米荧光素酶的具有复制能力的重组IAV毒株,该检测在人呼吸道细胞系上表现良好,并支持多周期感染。该方案小型化为384孔板形式,通过对一组美国国立卫生研究院临床收藏(NCC)进行一式四份筛选进行了验证。这些测试筛选显示了良好的检测参数和可重复性。在概念验证活动中应用于生物活性化合物LOPAC文库,检测到已获许可的抗黏液病毒治疗药物利巴韦林和神经氨酸酶抑制剂扎那米韦,并鉴定出两种意想不到的RSV特异性命中候选物,芬维A胺和阿片受体拮抗剂BNTX-7。使用表达海肾荧光素酶的标准recRSV报告毒株,在直接和正交剂量反应反筛选中对命中物进行了评估。

相似文献

2
Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening.
J Virol. 2016 Jul 27;90(16):7368-7387. doi: 10.1128/JVI.00898-16. Print 2016 Aug 15.
3
Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.
J Virol. 2013 Oct;87(20):11076-87. doi: 10.1128/JVI.01425-13. Epub 2013 Aug 7.
4
A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections.
J Virol. 2019 May 1;93(10). doi: 10.1128/JVI.00032-19. Print 2019 May 15.
5
High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors.
J Biomol Screen. 2015 Jun;20(5):597-605. doi: 10.1177/1087057115569428. Epub 2015 Feb 5.
7
Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00766-18. Print 2018 Aug.
9
Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):E3441-9. doi: 10.1073/pnas.1405198111. Epub 2014 Aug 4.
10
Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.
Antiviral Res. 2018 Feb;150:79-92. doi: 10.1016/j.antiviral.2017.10.012. Epub 2017 Oct 14.

引用本文的文献

1
Recombinant Influenza A Viruses Expressing Reporter Genes from the Viral NS Segment.
Int J Mol Sci. 2024 Oct 1;25(19):10584. doi: 10.3390/ijms251910584.
2
4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses.
PLoS Pathog. 2023 Apr 17;19(4):e1011342. doi: 10.1371/journal.ppat.1011342. eCollection 2023 Apr.
3
Treatment of Respiratory Viral Coinfections.
Epidemiologia (Basel). 2022 Feb 23;3(1):81-96. doi: 10.3390/epidemiologia3010008.
5
Generation of a pdmH1N1 2018 Influenza A Reporter Virus Carrying a mCherry Fluorescent Protein in the PA Segment.
Front Cell Infect Microbiol. 2022 Jan 20;11:827790. doi: 10.3389/fcimb.2021.827790. eCollection 2021.
6
Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity.
PLoS Pathog. 2021 Sep 27;17(9):e1009951. doi: 10.1371/journal.ppat.1009951. eCollection 2021 Sep.
7
Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
Int J Mol Sci. 2020 May 27;21(11):3812. doi: 10.3390/ijms21113812.
9
Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition.
Viruses. 2020 Mar 20;12(3):342. doi: 10.3390/v12030342.

本文引用的文献

1
GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.
Antimicrob Agents Chemother. 2015 Nov;59(11):7109-12. doi: 10.1128/AAC.00761-15. Epub 2015 Aug 31.
2
Tunable and reversible drug control of protein production via a self-excising degron.
Nat Chem Biol. 2015 Sep;11(9):713-20. doi: 10.1038/nchembio.1869. Epub 2015 Jul 27.
3
Blocking Respiratory Syncytial Virus Entry: A Story with Twists.
DNA Cell Biol. 2015 Aug;34(8):505-10. doi: 10.1089/dna.2015.2896. Epub 2015 May 11.
5
Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors.
Antimicrob Agents Chemother. 2015 Apr;59(4):2086-93. doi: 10.1128/AAC.04779-14. Epub 2015 Jan 26.
6
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.
Antiviral Res. 2015 Feb;114:1-10. doi: 10.1016/j.antiviral.2014.11.010. Epub 2014 Nov 28.
9
Oral GS-5806 activity in a respiratory syncytial virus challenge study.
N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184.
10
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
J Infect Dis. 2015 Jan 15;211(2):249-57. doi: 10.1093/infdis/jiu447. Epub 2014 Aug 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验